TD Asset Management Inc Has $853,000 Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)

Key Points

• TD Asset Management Inc significantly reduced its stake in NeoGenomics, decreasing its holdings by 57.5% in the first quarter, leaving it with approximately 0.07% of the company's stock.
• Several institutional investors, including Greenhouse Funds LLLP and Dimensional Fund Advisors LP, increased their positions in NeoGenomics during the fourth quarter, highlighting continued interest from larger investment firms.
• Analysts have downgraded NeoGenomics, with Leerink Partners lowering its price target from $25.00 to $9.00, while BTIG Research and others have shifted ratings to "neutral" or "hold."

TD Asset Management Inc lessened its position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 57.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 89,910 shares of the medical research company's stock after selling 121,522 shares during the quarter. TD Asset Management Inc owned about 0.07% of NeoGenomics worth $853,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NEO. Greenhouse Funds LLLP grew its position in NeoGenomics by 5.3% during the fourth quarter. Greenhouse Funds LLLP now owns 4,701,897 shares of the medical research company's stock worth $77,487,000 after buying an additional 237,491 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in NeoGenomics by 2.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,436,858 shares of the medical research company's stock valued at $56,645,000 after acquiring an additional 78,211 shares in the last quarter. First Light Asset Management LLC lifted its position in shares of NeoGenomics by 3.0% in the 4th quarter. First Light Asset Management LLC now owns 3,167,585 shares of the medical research company's stock worth $52,202,000 after acquiring an additional 91,030 shares during the period. Segall Bryant & Hamill LLC lifted its position in shares of NeoGenomics by 11.2% in the 1st quarter. Segall Bryant & Hamill LLC now owns 2,350,746 shares of the medical research company's stock worth $22,309,000 after acquiring an additional 236,924 shares during the period. Finally, Northern Trust Corp grew its holdings in shares of NeoGenomics by 7.4% during the 4th quarter. Northern Trust Corp now owns 1,621,809 shares of the medical research company's stock worth $26,727,000 after purchasing an additional 111,170 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company's stock.

NeoGenomics Price Performance

Shares of NEO traded down $0.12 during trading hours on Friday, hitting $5.65. The stock had a trading volume of 630,852 shares, compared to its average volume of 1,954,901. The stock has a market capitalization of $729.22 million, a price-to-earnings ratio of -6.97 and a beta of 1.54. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.92 and a quick ratio of 3.58. The company's fifty day moving average is $6.85 and its two-hundred day moving average is $9.07. NeoGenomics, Inc. has a 52 week low of $4.72 and a 52 week high of $19.11.

Insider Transactions at NeoGenomics

In other NeoGenomics news, Director Michael Aaron Kelly purchased 5,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 27th. The shares were acquired at an average cost of $7.60 per share, for a total transaction of $38,000.00. Following the transaction, the director directly owned 5,000 shares in the company, valued at approximately $38,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, COO Warren Stone acquired 5,700 shares of the business's stock in a transaction on Monday, May 12th. The stock was acquired at an average price of $8.58 per share, with a total value of $48,906.00. Following the transaction, the chief operating officer owned 108,280 shares in the company, valued at approximately $929,042.40. The trade was a 5.56% increase in their position. The disclosure for this purchase can be found here. 2.40% of the stock is owned by insiders.

Analysts Set New Price Targets

NEO has been the subject of a number of recent research reports. Leerink Partnrs lowered NeoGenomics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 30th. Morgan Stanley set a $8.00 price target on shares of NeoGenomics and gave the company an "equal weight" rating in a report on Wednesday, July 30th. Wall Street Zen upgraded shares of NeoGenomics from a "sell" rating to a "hold" rating in a research note on Tuesday, May 13th. Needham & Company LLC decreased their target price on shares of NeoGenomics from $8.50 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday, July 29th. Finally, Leerink Partners cut shares of NeoGenomics from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $25.00 to $9.00 in a research note on Wednesday, April 30th. Nine analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $12.75.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.